| Juliet Nellis, | |
|
117 2nd St, Apt 1, Aspinwall, PA 15215-2954 | |
| (412) 759-5789 | |
| Not Available |
| Full Name | Juliet Nellis |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 117 2nd St, Aspinwall, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790911758 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SL010518 (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Juliet Nellis, 117 2nd St, Apt 1, Aspinwall, PA 15215-2954 Ph: (412) 759-5789 | Juliet Nellis, 117 2nd St, Apt 1, Aspinwall, PA 15215-2954 Ph: (412) 759-5789 |
News Archive
Water Pik, Inc., a leading developer and manufacturer of innovative personal healthcare products, today announced the launch of the "Say No To String" advertising campaign to introduce consumers to the new Waterpik Water Flosser and to promote it as an easier and more effective alternative to traditional string floss.
Regenstrief Institute investigator Noll Campbell, PharmD, has been chosen by the American Geriatrics Society to receive a Merck/American Geriatrics Society 2012 New Investigator Award. He is the first doctor of pharmacy to receive this award, which is designed to recognize individuals who are committed to a career in aging research.
Roche's xCELLigence RTCA System is being used in the European Union's SEURAT (Safety Evaluation Ultimately Replacing Animal Testing) initiative to run five years from 2011 to 2016.
The most commonly used gene expression profile test used to help predict breast cancer recurrence may not be as cost-effective as once thought, say a team of researchers led by Georgetown Lombardi Comprehensive Cancer Center.
A comprehensive four-year project including over 10,000 patients in clinical and pharmacovigilance studies for diagnosis and treatment of visceral leishmaniasis (VL, also known as kala-azar) in India and Bangladesh was launched by an international consortium formed last month to support control and elimination strategies in both countries, where the concentration of disease burden is among the world's highest.
› Verified 8 days ago
Alexis P Monocello, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 27 4th St, Aspinwall, PA 15215 Phone: 814-823-2282 |